The use of the naturally occurring cannabinoid CBD is safe, well tolerated, and is not associated with any significant adverse public health effects, according to the findings of a preliminary report compiled by the World Health Organization’s Expert Committee on Drug Dependence. The agency is in the process of considering whether to place CBD within the agency’s international drug scheduling code.
Congressional leadership voted to enact a two-week continuing resolution that maintains present federal spending levels and priorities through December 22, 2017. The resolution extends medical cannabis patient protections imposed by the Rohrabacher-Blumenauer amendment until that date.
Sales of alcoholic beverages decline following the enactment of medical marijuana access laws, according to a working paper authored by a team of researchers from the University of Connecticut and Georgia State University. Researchers concluded: “States legalizing medical marijuana use experience significant decreases in the aggregate sale of alcohol, beer and wine. Moreover, the effects are not short-lived, with significant reductions observed up to 24 months after the passage of the law.”